Although the phase I results were promising, with some patients demonstrating improvements in left ventricular structure and function, the subsequent CUPID2 trial revealed that AAV1/SERCA2a therapy failed to reduce HF recurrence or delay terminal events
Early phases may show faster results, with gradual tapering over time
The analyses assessed three GLP-1 receptor agonists and found that each contributed to notable weight reduction compared to placebo
As demand grows and more options enter the market, prices are starting to come down, a welcome change for patients whove been waiting for a more budget-friendly path to a healthier lifestyle
Tesamorelin works on the body through the pituitary gland, so it should not be administered to test subjects with disorders that disrupt that system
Genetic polymorphisms in NAT2 (N-acetyltransferase 2), TPMT (thiopurine methyltransferase), and glutathione S-transferase genes create phenotypic differences